What Fimasartan Treats: Main Uses and Benefits

Fimasartan is commonly used to help with essential hypertension (high blood pressure), a primary condition involving symptoms related to heightened physiological activity that creates noticeable physiological strain. This medication is applied across domains where additional symptomatic support is needed. It is relevant for easing symptoms in conditions involving systemic imbalance and organ-specific functional stress, such as hypertension and the supportive management of chronic heart failure.

In relevant clinical settings, Fimasartan may be part of a regimen for conditions where functional stability becomes affected. This treatment is used for managing symptom clusters and helps improve day-to-day comfort during symptomatic periods. This medication contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress. By effectively addressing systemic imbalance, its application may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Heightened Physiological Activity

Regulatory References

1. National Drug Information on Kanarb (Fimasartan)

Who Can and Cannot Use Fimasartan?

The population eligibility for Fimasartan is strictly defined by official regulatory guidelines, separating adult patients for whom use is established from those populations for whom use is restricted or prohibited.

Contraindicated Populations

Fimasartan is contraindicated and must not be used by specific groups. The most critical exclusion is pregnancy (especially the second and third trimesters) due to the risk of fetal harm. Use is also prohibited in patients with known hypersensitivity to the drug and in those with moderate to severe hepatic impairment (Child-Pugh Class B or C). Additionally, the drug is contraindicated for patients with diabetes mellitus who are concurrently receiving Aliskiren.

Restricted and Non-Established Use

• Pediatric Patients (≤ 18 years old): Efficacy and safety have not been established in this age group.
• Severe Renal Impairment ( CrCl < 30 mL/min): Use is conditional, requiring mandatory initial dose adjustment and close monitoring.
• Lactation (Breastfeeding): Use is not recommended.
• Adults (Standard Use): Approved for use in the adult patient population.

Fimasartan Interactions with other medicines and products

The interaction profile of Fimasartan is categorized by pharmacokinetic exposure modification and pharmacodynamic additive risk, as documented in regulatory information.

Pharmacokinetic Interactions

Fimasartan is a substrate for both the CYP3A4 enzyme and the OATP1B1 drug transporter. Co-administration with certain inhibitors leads to increased systemic exposure:

• Rifampicin (a strong OATP1B1 inhibitor) increases Fimasartan systemic exposure ( AUC) by 4.6-folds. Regulatory sources do not recommend this combination.
• Ketoconazole (a CYP3A4 inhibitor) increases Fimasartan exposure ( AUC) by 2-folds.
• Co-administration with Atorvastatin is documented to increase Fimasartan's peak plasma concentration ( C max,ss) by 2.18-fold.

Pharmacodynamic Interactions

Interactions involving similar physiological effects carry an additive risk, as noted for the Angiotensin II Receptor Blocker (ARB) class:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant use increases the documented risk of renal impairment and hyperkalemia.
• Dual Inhibition of the RAS: Combining Fimasartan with another RAS blocker (e.g., ACE inhibitors or Aliskiren) increases the risk of renal impairment, hypotension, and hyperkalemia.

Population-Specific Constraints

Fimasartan is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C), as studies show systemic exposure can be increased by over five-fold in this population. No specific timing separation rules regarding food are mandated in the regulatory documents.

Fimasartan is a non-peptide angiotensin II type 1 receptor (AT1) antagonist. Its mechanism of action involves competitive binding to the AT1 receptor, which is expressed in various tissues, including vascular smooth muscle, the heart, adrenal glands, and kidneys. Angiotensin II normally acts as the endogenous agonist, binding to the AT1 receptor and activating the intracellular signaling cascade involving Gq protein coupling and subsequent activation of phospholipase C (PLC). This leads to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), resulting in an increase in intracellular Ca^2+ concentration and the activation of protein kinase C (PKC). Fimasartan's antagonistic interaction blocks the ability of angiotensin II to occupy and activate the AT1 receptor.

The resulting inhibition of the Gq-mediated signaling pathway prevents the rise in intracellular Ca^2+. At the systemic level, this action reduces the AT1 receptor-mediated vasoconstrictive effects, decreases aldosterone release from the adrenal cortex, and modulates renal sodium and water handling.

How Fimasartan is Used: Official Administration Guidelines

Fimasartan is administered according to established protocols. It is an oral tablet taken once daily (OD). The usage is standardized by specific dosing tiers and adjustments for certain patient groups, ensuring adherence to verified product characteristics.

---

Official Dosing and Frequency

Administration Component	Standard Instruction
Route and Form	Oral Tablet
Frequency	Once daily (OD), preferably at the same time each day.
Food Intake	May be taken with or without food.
Initial Adult Dose	60 mg once daily.
Titration/Maximum Dose	May be increased to 120 mg once daily if blood pressure is not adequately controlled.
Full Effect Time	Maximal blood pressure reduction is typically attained after 8 to 12 weeks of treatment.

---

Population-Specific Adjustments

Specific dose adjustments are used in certain populations to ensure proper use:

• Severe Renal Impairment (Creatinine Clearance < 30 mL/min): The recommended initial dose is 30 mg once daily and should not exceed 60 mg once daily.
• Volume-Depleted Patients (e.g., those on high-dose diuretics): A reduced initial dose of 30 mg once daily is recommended.
• Older Adults (over 70 years): No initial dosage adjustment is required.
• Hepatic Impairment: Not recommended for use in moderate to severe impairment.

These instructions define the single oral route, the dosing schedule, and the specific adjustments necessary for patients with impaired renal function or low blood volume.

Research Evidence / Overview of Studies for Fimasartan

---

Evidence for Use in Essential Hypertension (High Blood Pressure)

The main research base for Fimasartan involves short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving high blood pressure, and they typically compared Fimasartan to an inactive substance (placebo) or to other established medicines in the same drug class. Studies monitored outcomes reflecting physiological strain and consistently measured the change in blood pressure—both when taken in the clinic and using 24-hour Ambulatory Blood Pressure Monitoring (ABPM). Studies monitored the overall patterns in blood pressure levels over a defined time interval, usually lasting 8 to 12 weeks.

In these trials, research described the measurement of changes in blood pressure values across the different study groups. The research highlights measurements of the proportion of patients who reached specified target blood pressure readings. Additionally, large-scale post-marketing observational studies explored short-term changes and described patterns related to the need for adding other blood pressure medicines over several months of use. What remains uncertain is the full picture of the very long-term effects, as the evidence base is focused predominantly on short-term and intermediate follow-up durations.

---

Research on Cardiovascular Parameters

Beyond the primary studies for blood pressure, research has also explored Fimasartan in contexts related to other cardiovascular markers. Studies looked at outcomes related to systemic or functional imbalance, specifically investigating the heart’s structure and function. This included smaller-scale randomized comparative trials that researched parameters such as the Left Ventricular Mass (LVM) index. Moreover, Fimasartan was evaluated in preclinical research using animal models where studies explored outcomes linked to inflammatory states, such as tissue damage after injury.

---

Evidence in Specific Patient Groups

Research has monitored the use of Fimasartan in adults with essential hypertension across a range of ages. Subgroup analyses were applied in studies examining how elderly patients reported their experience. Furthermore, research explored the use of Fimasartan in patient groups with co-existing health issues, including studies with patients who have diabetes and those with mild chronic liver disease. The findings describe group patterns observed in these studies, but sample sizes for specific subgroup analyses were limited, meaning results apply only to the populations studied in the research context.

Key Studies & References

1. The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics

Common questions about Fimasartan (FAQ)

Q: What is Fimasartan used for?

Fimasartan is indicated for the treatment of essential hypertension (high blood pressure). It is used to help lower blood pressure, which may reduce the risk of associated cardiovascular events.

---

Q: When is the best time of day to take Fimasartan?

Fimasartan is typically taken once daily. The official product information generally states that the medication can be taken with or without food. For consistency and to support adherence, it is often recommended to take the dose at the same time each day. Your doctor will provide the most specific guidance.

---

Q: Can Fimasartan affect my kidney function?

As with other medications in its class, Fimasartan can influence kidney function. Your healthcare provider will usually monitor your kidney function through blood tests (such as serum creatinine and blood urea nitrogen) before starting treatment and regularly thereafter, especially during the first few months. If you have a pre-existing kidney condition, this monitoring is crucial.

---

Q: What are the common side effects of Fimasartan?

The most commonly reported side effects in clinical trials include headache, dizziness, and fatigue. Most side effects are generally mild and may decrease as your body adjusts to the medication. It is important to discuss any persistent or bothersome side effects with your healthcare provider.

Storage and Disposal Requirements for Fimasartan

Fimasartan tablets must be stored under specific conditions to maintain their stability and effectiveness, as defined by regulatory labeling.

Storage Conditions

• Store the tablets at a temperature below 30°C.
• The medication must be kept in the original container to ensure protection from light and moisture.
• It is mandatory to store Fimasartan out of the sight and reach of children.

Disposal Instructions

• Unused or expired Fimasartan must not be thrown away in household waste or flushed down the toilet (via wastewater).
• The medication should be disposed of in accordance with local regulatory requirements; consult a pharmacist for guidance on proper pharmaceutical waste disposal.